Indatraline

Indatraline is a non-selective monoamine transporter inhibitor that was researched as a potential treatment for cocaine addiction and depression. It was developed in the 1990s by the pharmaceutical company Eli Lilly and Company.

Pharmacology

Indatraline inhibits the reuptake of serotonin, norepinephrine, and dopamine by binding to the transporters, and this leads to increased extracellular concentrations of these neurotransmitters and therefore an increase in neurotransmission.

Development and Research

Indatraline was developed by Eli Lilly and Company in the 1990s. It was researched as a potential treatment for depression and cocaine addiction. In animal studies, indatraline was shown to reduce cocaine use. However, development was discontinued due to the risk of seizures.

Side Effects

The most serious side effect of indatraline is the risk of seizures, which led to the discontinuation of its development. Other side effects include insomnia, nausea, and headache.

See Also

• Monoamine transporter
• Cocaine addiction
• Depression

Indatraline Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski